Efficacy and Safety of First-Line Everolimus Therapy Alone or in Combination with Octreotide in Gastroenteropancreatic Neuroendocrine Tumors. A Hellenic Cooperative Oncology Group (HeCOG) Study
The purpose of this study was to explore the efficacy and safety of everolimus administered as a first-line treatment in newly diagnosed patients with metastatic or inoperable gastroenteropancreatic neuroendocrine tumors (GEP NETs). This phase II, multicenter, single-arm study included patients with...
Main Authors: | Anna Koumarianou, Dimitrios Pectasides, Georgia-Angeliki Koliou, Dimitrios Dionysopoulos, Dionysia Kolomodi, Christos Poulios, Maria Skondra, Joseph Sgouros, George Pentheroudakis, Gregory Kaltsas, George Fountzilas |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Biology |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-7737/9/3/51 |
Similar Items
-
Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET
by: Simron Singh, et al.
Published: (2024-01-01) -
Incidence of gall stone formation in acromegalic patients on octreotide therapy
by: Aditi A Chakravarty, et al.
Published: (2012-01-01) -
The use of octreotide in the treatment of chylothorax
by: Hıdır Esme
Published: (2019-12-01) -
Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
by: Krzysztof Kaliszewski, et al.
Published: (2022-04-01) -
Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling
by: Hendrik Ungefroren, et al.
Published: (2022-12-01)